Single-oral-dose azithromycin prophylaxis against experimental streptococcal or staphylococcal aortic valve endocarditis

A Tsitsika; A Pefanis; G S Perdikaris; I Donta; P Karayiannakos; H Giamarellou

doi:10.1128/AAC.44.6.1754-1756.2000

Single-oral-dose azithromycin prophylaxis against experimental streptococcal or staphylococcal aortic valve endocarditis

Antimicrob Agents Chemother. 2000 Jun;44(6):1754-6. doi: 10.1128/AAC.44.6.1754-1756.2000.

Authors

A Tsitsika¹, A Pefanis, G S Perdikaris, I Donta, P Karayiannakos, H Giamarellou

Affiliation

¹ Infectious Diseases Section, 4th Department of Medicine, Sismanoglion General Hospital, Athens University School of Medicine, Athens, Greece.

Abstract

Azithromycin and ampicillin protected 94 and 72% of animals challenged with Streptococcus oralis, respectively (P = 0.177), while azithromycin and vancomycin protected 59 and 94% of the methicillin-resistant Staphylococcus aureus (MRSA)-challenged animals, respectively (P = 0.018). Azithromycin is effective in preventing experimental streptococcal endocarditis, but against MRSA it is less effective than vancomycin.

MeSH terms

Administration, Oral
Animals
Anti-Bacterial Agents / administration & dosage*
Aortic Valve / microbiology
Azithromycin / administration & dosage*
Endocarditis, Bacterial / drug therapy*
Female
Rabbits
Staphylococcal Infections / drug therapy*
Streptococcal Infections / drug therapy*

Substances

Anti-Bacterial Agents
Azithromycin